Deuterated compounds and uses thereof
The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
1. A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is selected from —NH 2 , —NHD, or —ND 2 ;
R 2 is selected from hydrogen or deuterium;
R 3 and R 4 are each —CD 3 ; and
R 5 , R 6 , R 7 , and R 8 are each independently selected from hydrogen or deuterium.
2. The compound according to claim 1 , wherein each of R 5 , R 6 , R 7 , and R 8 is as defined in one of the following entries:
Entry
R 5
R 6
R 7
R 8
i
H
H
H
H
ii
H
H
H
D
iii
H
H
D
H
iv
H
D
H
H
v
D
H
H
H
vi
D
H
H
D
vii
D
H
D
H
viii
D
D
H
H
ix
H
D
H
D
x
H
D
D
H
xi
H
H
D
D
xii
H
D
D
D
xiii
D
H
D
D
xiv
D
D
H
D
xv
D
D
D
H
xvi
D
D
D
D.
3. The compound of claim 1 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable adjuvant, carrier, or vehicle.
5. The pharmaceutical composition according to claim 4 , in combination with an additional therapeutic agent.
6. The compound of claim 1 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of about 50% or greater.
7. The compound of claim 1 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of about 70% or greater.
8. The compound of claim 1 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of about 80% or greater.
9. The compound of claim 1 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of about 90% or greater.
10. The compound of claim 1 , wherein at least one position of deuterium enrichment in the compound comprises deuterium in an amount of about 90% or greater.
11. The compound of claim 1 , wherein each position of deuterium enrichment in R 3 and R 4 comprises deuterium in an amount of about 50% or greater.
12. The compound of claim 1 , wherein each position of deuterium enrichment in R 3 and R 4 comprises deuterium in an amount of about 90% or greater.
13. The compound of claim 1 , wherein each position of deuterium enrichment in R 3 and R 4 comprises deuterium in an amount of 95% or greater.
14. The compound of claim 2 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of about 90% or greater.
15. The compound of claim 3 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of about 50% or greater.
16. The compound of claim 3 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of about 70% or greater.
17. The compound of claim 3 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of about 90% or greater.
18. The compound of claim 3 , wherein at least one position of deuterium enrichment in the compound comprises deuterium in an amount of about 90% or greater.
19. A compound of the following structure:
or a pharmaceutically acceptable salt thereof; wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of 70% or greater.
20. The compound of claim 19 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of 90% or greater.